相关实验视频
Updated: Feb 28, 2026

07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
Circ_0057105通过海绵化miR-1290和调节MDM2/P53通路促进肝内胆管癌的进展
Taiyang Chen1, Yangyang Wang1, Chenxi Xie1
1Hepatobiliary Center, Department of Hepatobiliary Surgery, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
Cellular signalling
|February 26, 2026
概括
一种新发现的循环RNA,circ_0057105,通过抑制p53通路来驱动肝内胆管癌 (ICC) 的进展. 用siRNA准circ_0057105为这种侵袭性癌症提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 在RNA生物学,RNA生物学.
背景情况:
- 肝脏内胆管癌 (ICC) 是一种具有不良预后的侵袭性肝癌.
- 治疗选择有限,需要发现新的调节分子和治疗点.
- 循环RNAs (circRNAs) 正在成为癌症发展中的关键参与者.
研究的目的:
- 为了识别参与ICC病变的新型circRNAs.
- 为了阐明ICC中circ_0057105的分子机制.
- 评估circ_0057105作为预后生物标志物和治疗标.
主要方法:
- 高通量测序ICC和相邻的正常组织.
- 在ICC细胞系和临床样本中进行验证.
- 在体外和体外功能测定 (扩散,迁移,入侵).
- 涉及RNA免疫沉降和西式涂抹的机制研究.
- 在体内治疗评估使用脂质纳米颗粒输送的siRNA.
主要成果:
- Circ_0057105在ICC组织中显著上调,与患者预后不佳相关.
- Circ_0057105促进了ICC细胞的增殖,迁移和入侵.
- Circ_0057105作为一个竞争的内源RNA (ceRNA) 起作用,使miR-1290变为海绵,上调MDM2.
- MDM2针对瘤抑制剂p53进行降解,抑制p53信号通路.
- 在体内通过脂质纳米颗粒输送si-circ_0057105抑制了瘤生长.
结论:
- 电路_0057105驱动通过miR-1290-MDM2-p53轴的ICC进展.
- Circ_0057105是ICC的一个有前途的预后生物标志物.
- 用脂质纳米粒子封装的siRNA准circ_0057105代表了ICC的一个潜在的治疗策略.
更多相关视频
相关概念视频
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
Induced Pluripotent Stem Cells
5.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.7K
PI3K/mTOR/AKT Signaling Pathway
5.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.9K

